Navigation Links
Galectin Therapeutics Reports Full Year and Fourth Quarter 2012 Financial Results
Date:3/29/2013

k related to the PROCAPS agreement which we terminated in 2012 and decreased litigation costs related to a settlement in 2011.

About Galectin TherapeuticsGalectin Therapeutics (NASDAQ: GALT) is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, key mediators of biologic function.  We are leveraging extensive scientific and development expertise as well as established relationships with external sources to achieve cost effective and efficient development.  We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer.  Additional information is available at www.galectintherapeutics.com.

Forward Looking StatementsThis press release contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  These statements relate to future events or future financial performance, and use words such as "may," "estimate," "could," "expect" and others.  They are based on our current expectations and are subject to factors and uncertainties which could cause actual results to differ materially from those described in the statements.  Factors that could cause our actual performance to differ materially from those discussed in the forward-looking statements include, among others: incurrence of operating losses since our inception, uncertainty as to adequate financing of our operations, extensive and costly regulatory oversight that could restrict or prevent product commercialization, inability to achieve commercial product acceptance, inability to protect our intellectual property, dependence on strategic partnerships, product c
'/>"/>

SOURCE Galectin Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Galectin-3 Assessed as a Biomarker of Heart Failure: Key Clinical Trial Findings Published by Dove Medical Press
2. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
3. Nile Therapeutics Reports 2011 Third Quarter Financial Results
4. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
5. Fate Therapeutics Strengthens Its iPSC Platform
6. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
7. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
8. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
9. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
10. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
11. Aratana Therapeutics Completes $15 Million Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 2014 iLab Solutions, the leader in core ... Director of Product Strategy. In this role, Michelle will work ... to guide in the development of iLab products. Her main ... possible benefit to the scientific community by offering the most ...
(Date:1/14/2014)...  RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology company ... addressing major unmet medical needs using RNA-targeted technologies, ... Allowance from the United States Patent and Trademark ... for the treatment of fibrosis. The patent covers ...
(Date:1/14/2014)... 14, 2014   Kinaxis ®, provider of RapidResponse ®, ... and operations planning ( S&OP ) service, is proud to ... which will be held at the Hilton San Diego Bayfront, ... customer Elisabeth Kaszas , Director of Supply Chain at ...
(Date:1/14/2014)... CA (PRWEB) January 14, 2014 Kerr Corporation, ... 10-minute video and additional how-to information about dual arch impressions ... Restorations with Dual Arch Impressions,” the blog entry serves up ... technique and houses a step-by-step demonstration by Dr. David Little ...
Breaking Biology Technology:iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... hair-like blood vessels in the back of our eyes, researchers ... those that bring blood to the heart respond to air ... otherwise healthy people exposed to high levels of air pollution ... of heart disease. Previous studies linked pollution to heart ...
... An international team of researchers has succeeded in creating ... for the first time, allowing them to examine the ... the University of Leeds, the US Department of Energy,s ... Facilities Council,s Rutherford Appleton Laboratory say the breakthrough will ...
... Mass. -- Researchers at Tufts University School of Engineering have ... and two variations, using E. coli as the ... 24, 2010, issue of Chemistry and Biology, offers ... new drugs that will combat the growing incidence of antibiotic ...
Cached Biology Technology:Photos of tiny blood vessels in the eye link air pollution to heart disease 2Scientists create highly ordered artificial spin ice using nanotechnology 2Scientists create highly ordered artificial spin ice using nanotechnology 3Erythromycin A produced in E. coli for first time 2
(Date:4/23/2014)... in their mid-thirties and forties, face a devastating ... two decades. "Mutant" protein clusters, long blamed for ... the primary focus of therapies in development by ... Prof. Gerardo Lederkremer and Dr. Julia Leitman of ... Immunology, in collaboration with Prof. Ulrich Hartl of ...
(Date:4/23/2014)... Toronto Scarborough research shows that male black widow spiders ... a rare example of mate preference by male spiders. ... Emily MacLeod and Maydianne Andrade, a professor in UTSC,s ... studies and the wild that males overwhelmingly chose to ... black widows can tell whether a potential mate is ...
(Date:4/23/2014)... source of a unique rhythmic sound, recorded for decades ... the Antarctic minke whale ( Balaenoptera bonaerensis ). First ... who thought it sounded like a duck, the bio-duck ... Southern Ocean, but its source has remained a mystery, ... of researchers deployed acoustic tags on two Antarctic minke ...
Breaking Biology News(10 mins):On the defensive 2On the defensive 3Picky male black widow spiders prefer well-fed virgins 2Scientists identify source of mysterious sound in the Southern Ocean 2Scientists identify source of mysterious sound in the Southern Ocean 3
... have uncovered a dramatic new twist in the battle against ... itself immune to a key component of the only effective ... team of TB researchers at Leicester announced a new advance ... They isolated the molecular weapons of the bacterium and are ...
... spring arrives across the country, tourists returning to beaches will ... algae that make water unfit for swimming and pose risks ... realize is that the small streams running through their neighborhoods ... feeds the algae blooms. A new study published in ...
... RIDGE, Tenn., March 12, 2008 -- Noted green energy ... this years Global Venture Challenge, a business competition and ... Ridge National Laboratory. The focus of this years ... bioenergy, energy efficiency and power generation sectors. Sridhar, ...
Cached Biology News:Scientists discover how TB 'develops invincibility' against only available treatment 2From the backyard to the ocean: New study shows streams act as key nitrogen filters 2
Procollagen type I C-terminal propeptide (human, PICP)...
... in Early Drug Development with Imaging Mass ... drug compound localization data in early drug ... mass spectrometry service maps unlabeled ... so you can localize drugs and metabolites ...
... LC Sciences provides a unique new ... DNA synthesis serving diverse needs in genomics, ... applications. OligoMix is a MIXTURE of a ... sequences delivered in a single microtube. OligoMix ...
... is an automated, high-resolution protein analysis ... ProteomeLab family of products, the PA ... automated protein characterization solutions including molecular ... carbohydrate profiling and mechanisms to study ...
Biology Products: